Drugs / PH FDC SC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04802759 | Jun 2021 → May 2029 expected | estrogen-receptor positive breast cancer | Hoffmann-La Roche | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PH FDC SC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04802759 ↗ |
| Route | Subcutaneous | “will be administered SC” NCT04802759 ↗ |